Form 8-K - Current report:
SEC Accession No. 0001564590-22-012316
Filing Date
2022-03-30
Accepted
2022-03-30 07:40:23
Documents
13
Period of Report
2022-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ortx-8k_20220330.htm   iXBRL 8-K 42266
2 EX-99.1 ortx-ex991_7.htm EX-99.1 121486
  Complete submission text file 0001564590-22-012316.txt   305804

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ortx-20220330.xsd EX-101.SCH 5701
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ortx-20220330_lab.xml EX-101.LAB 18595
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ortx-20220330_pre.xml EX-101.PRE 11109
7 EXTRACTED XBRL INSTANCE DOCUMENT ortx-8k_20220330_htm.xml XML 3469
Mailing Address 108 CANNON STREET LONDON X0 EC4N 6EU
Business Address 108 CANNON STREET LONDON X0 EC4N 6EU 011-44-0-203-3846700
Orchard Therapeutics plc (Filer) CIK: 0001748907 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38722 | Film No.: 22783167
SIC: 2836 Biological Products, (No Diagnostic Substances)